BeiGene To Become First Tri-Listed Biotech Amid Offer Price Concerns

 
• By Dexter Jie Yan
  
Stock Exchange STAR Market
BeiGene's Shanghai IPO price draws investor concerns in China. • Source: Alamy

More from China

More from Focus On Asia